Farallon Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16M | Hold |
|
|||||
|
2025
Q1 | $11.7M | Buy |
|
|||||
|
2024
Q4 | $12.1M | Hold |
|
|||||
|
2024
Q3 | $21.8M | Buy |
|
|||||
|
2024
Q2 | $27.2M | Hold |
|
|||||
|
2024
Q1 | $36.6M | Buy |
|
|||||
|
2023
Q4 | $19.1M | Buy |
|
|||||
|
2023
Q3 | $20.9M | Hold |
|
|||||
|
2023
Q2 | $40.1M | Buy |
|
|||||
|
2023
Q1 | $62.7M | Hold |
|
|||||
|
2022
Q4 | $72.1M | Hold |
|
|||||
|
2022
Q3 | $80.4M | Hold |
|
|||||
|
2022
Q2 | $73.3M | Hold |
|
|||||
|
2022
Q1 | $110M | Sell |
|
|||||
|
2021
Q4 | $118M | Sell |
|
|||||
|
2021
Q3 | $113M | Hold |
|
|||||
|
2021
Q2 | $87.8M | Hold |
|
|||||
|
2021
Q1 | $98.4M | Buy |
|
|||||
|
2020
Q4 | $74.7M | Hold |
|
|||||
|
2020
Q3 | $81.3M | Buy |
|
|||||
|
2020
Q2 | $87.9M | Hold |
|
|||||
|
2020
Q1 | $90M | Hold |
|
|||||
|
2019
Q4 | $108M | Buy |
|
|||||
|
2019
Q3 | $76.6M | Buy |
|
|||||
|
2019
Q2 | $81M | Buy |
|
|||||
|
2019
Q1 | $89.8M | Buy |
|
|||||
|
2018
Q4 | $65.5M | Buy |
|
|||||
|
2018
Q3 | $74.1M | Sell |
|
|||||
|
2018
Q2 | $125M | Buy |
|
|||||
|
2018
Q1 | $74M | Sell |
|
|||||
|
2017
Q4 | $54.3M | Buy |
|
|||||
|
2017
Q3 | $19.3M | Buy |
|